Last update 24 Sep 2025

ALXN-1920

Overview

Basic Info

Drug Type
Protein drugs
Synonyms
ALXN 1920, ALXN1920
Target-
Action-
Mechanism-
Therapeutic Areas
Immune System DiseasesUrogenital DiseasesOther Diseases
Active Indication
Idiopathic Membranous GlomerulonephritisKidney Diseases
Inactive Indication-
Originator Organization
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
Active Organization
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.AstraZeneca Global R&D (China) Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with ALXN-1920
NCT07157787
/ RecruitingPhase 2
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants With PMN (Primary Membranous Nephropathy) Who Are at a High Risk for Disease Progression
NCT05751642
/ CompletedPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1920 in Healthy Adult Participants
100 Clinical Results associated with ALXN-1920
Login to view more data
100 Translational Medicine associated with ALXN-1920
Login to view more data
100 Patents (Medical) associated with ALXN-1920
Login to view more data
100 Deals associated with ALXN-1920
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Idiopathic Membranous GlomerulonephritisPhase 2
United States
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
China
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
Argentina
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
Australia
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
Brazil
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
France
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
Italy
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
Spain
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
Taiwan Province
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Idiopathic Membranous GlomerulonephritisPhase 2
United Kingdom
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
19 Sep 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free